Cargando…
Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome
Atypical hemolytic uremic syndrome (aHUS) is a rare cause of end-stage kidney disease and associated with poor outcomes after kidney transplantation from early disease recurrence. Prophylactic eculizumab treatment at the time of transplantation is used in selected patients with aHUS. We report a ret...
Autores principales: | Glover, Emily K., Smith-Jackson, Kate, Brocklebank, Vicky, Wilson, Valerie, Walsh, Patrick R., Montgomery, Emma K., Wong, Edwin K.S., Johnson, Sally, Malina, Michal, Kavanagh, David, Sheerin, Neil S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065821/ https://www.ncbi.nlm.nih.gov/pubmed/36413152 http://dx.doi.org/10.1097/TP.0000000000004355 |
Ejemplares similares
-
Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study
por: Brocklebank, Vicky, et al.
Publicado: (2023) -
Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report
por: Sevinc, Mustafa, et al.
Publicado: (2015) -
Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland
por: Brocklebank, Vicky, et al.
Publicado: (2017) -
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018)